By: Daniel Trecroci
On April 20, 2006, Eli Lilly & Co. told Diabetes Health that the U.S. Food and Drug Administration has granted priority review status for Arxxant, its potential “first-in-class treatment” for diabetic retinopathy.
Diabetic retinopathy is a result of damage to the small blood vessels in the back of the eye caused by diabetes. According to Eli Lilly, about 40 to 45 percent of Americans diagnosed with diabetes have some stage of diabetic retinopathy, which can lead to vision loss and blindness.
“Currently, there are no approved prescription products to treat diabetic retinopathy, says Eli Lilly. “Arxxant has the potential to represent a significant improvement in the treatment of diabetic retinopathy.”